# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sun Yat-sen (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET016-SYN-TD
- Date: 1924-05-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Wen-Li Huang, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- He has had a dull ache under his right ribs, early fullness and weight loss for three months, and can feel a firm lump there himself **S**
- As a physician by training he wants to see his images and results himself, to be told plainly, and to be cared for on the same pathway as any other patient **S**
- He wants to keep working and traveling for as long as he can **S**

## Your goals

- Tissue diagnosis and complete staging within four weeks of the first visit. Target: 1924-06-01. Recorded outcome: Biopsy diagnosis in nine days and staging complete by laparoscopy in about three and a half weeks. **S**
- Right upper abdominal pain at 3 of 10 or less, with full days of work possible (ECOG 0 to 1). Target: 1924-10-26. Recorded outcome: Ache 0 to 2 of 10 on acetaminophen as needed; ECOG 1 throughout. **S**
- Weight held within 2 kg of the weight at the start of treatment. Target: 1924-10-26. Recorded outcome: 60.0 kg at cycle 1 and 59.6 kg at cycle 8. **S**
- Goals of care and a health care agent documented, and revisited as treatment changes. Target: 1924-09-21. Recorded outcome: Agent named and goals recorded with palliative care and at the preventive visit. **S**
- Complete first-line chemoimmunotherapy without grade 3 or higher toxicity. Target: 1924-10-26. Recorded outcome: Seven cycles given by the last visit with grade 1 toxicity only; the eighth started that day. **S**

## What we agreed to do

- Work-up of the liver mass: multiphase contrast CT of the liver with CT of the chest, abdomen and pelvis; MRI of the liver with MRCP if CT does not settle the origin; alpha-fetoprotein, CA 19-9 and CEA; hepatitis B surface antigen, core antibody and surface antibody, and hepatitis C antibody; liver function with Child-Pugh and ALBI scoring; and image-guided core biopsy, because a mass in a liver without cirrhosis cannot be diagnosed by imaging alone. Guideline: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023) **S**
- Medical oncology consultation for a solid liver mass with weight loss: diagnosis, staging, multidisciplinary tumor board review, and treatment. Guideline: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023) **S**
- Symptom care during the work-up: acetaminophen up to 3,000 mg a day, small frequent meals with a dietitian's advice, weight at every visit, and a same-day call for jaundice, fever, vomiting, dark urine or worse pain; results shared with him in full as they arrive, by one coordinating clinician. Guideline: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026) **S**
- Staging laparoscopy before any attempt at resection, with biopsy of any peritoneal disease and an implanted port under the same anesthetic; if no metastases, extended cholecystectomy with resection of liver segments IVb and V and portal lymphadenectomy; comprehensive genomic profiling of the biopsy tissue (HER2, mismatch repair and microsatellite status, BRAF, FGFR2, IDH1, NTRK, RET, KRAS, tumor mutational burden). Guideline: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026) **S**
- Hepatitis B reactivation monitoring for resolved infection (surface antigen negative, core antibody positive, HBV DNA undetectable): HBV DNA and ALT every 3 months during treatment and for at least 6 to 12 months after, with entecavir started promptly if HBV DNA becomes detectable or surface antigen reappears. Guideline: Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020) **S**
- First-line systemic therapy for stage IVB gallbladder adenocarcinoma: gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8 with durvalumab 1,500 mg on day 1 every 21 days for up to 8 cycles, then durvalumab 1,500 mg every 4 weeks until progression or unacceptable toxicity; blood count, creatinine, magnesium and liver tests before each dose; TSH every cycle; CA 19-9 each cycle; CT of the chest, abdomen and pelvis every 2 to 3 months; teaching on immune-related side effects; ondansetron at home. Guideline: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021) **S**
- Specialist palliative care alongside cancer treatment from the diagnosis of advanced disease: symptoms, nutrition, coping, goals of care, a health care agent, and a family meeting if and when he chooses. Guideline: Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017) **S**
- Magnesium oxide 400 mg by mouth daily for cisplatin-related low magnesium, rechecked with each dose; durvalumab maintenance every 4 weeks after the eighth cycle, with restaging CT every 2 to 3 months. Guideline: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022) **S**

## Follow-up

- 1924-05-04: New patient with a right upper abdominal mass, aching and weight loss: work-up of a liver mass, symptom care, and how he wants to receive results **S**
- 1924-05-18: Biopsy and imaging results and medical oncology consultation; diagnosis, staging plan, and hepatitis B status **S**
- 1924-06-01: Staging laparoscopy result and tumor board recommendation; first cycle of chemoimmunotherapy and specialist palliative care **S**
- 1924-08-03: Before cycle 4: restaging CT, tumor marker, toxicity review, hepatitis B monitoring, and genomic profiling result **S**
- 1924-09-21: Periodic adult preventive visit **S**
- 1924-10-26: Before cycle 8: restaging CT, toxicity review, low magnesium, and the plan for maintenance durvalumab **S**

This teaching document does not replace care from a qualified clinician.
